TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14519613
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for depression and parenting skills enhancement
Study: 8774276
Drug: Endometrial biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsy followed by IM injection of 5,000 IU hCG
Study: 1727843
Drug: Red light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red light therapy
Study: 1727843
Drug: Infrared light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared light therapy
Study: 6091474
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of ceftriaxone
Study: 6091474
Drug: Multidose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose cefazolin (one preoperative and three postoperative doses)
Study: 26479973
Drug: 3-dose MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose MenACWY-CRM vaccination series
Study: 26479973
Drug: 4-dose MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose MenACWY-CRM vaccination series
Study: 26479973
Drug: 3-dose MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose MenACWY-CRM with PCV13
Study: 26479973
Drug: 4-dose MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose MenACWY-CRM with PCV13
Study: 25269467
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed through skin flaps
Study: 25269467
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed through oral mucosa
Study: 23096987
Drug: Acellular dermal
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular dermal matrix‐assisted, tissue expander/implant reconstruction
Study: 23096987
Drug: Submuscular tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submuscular tissue expander/implant placement
Study: 12243599
Drug: 5 mL/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg/d of amniotic fluid solution
Study: 12243599
Drug: 10 mL/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/d of amniotic fluid solution
Study: 12243599
Drug: 20 mL/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg/d of amniotic fluid solution
Study: 30153580
Drug: Phosphorus (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus (500 mg) with a high-carbohydrate meal
Study: 21098520
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus midazolam
Study: 21098520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Acetaminophen alone)
Study: 3806894
Drug: Intradermal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal human diploid cell rabies vaccine (ID HDCV)
Study: 29241421
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate capsules every 72 hours for 1 month)
Study: 20705223
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat gain
Study: 15958805
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of MLN02 per kilogram
Study: 15958805
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg of MLN02 per kilogram
Study: 10325259
Drug: Percutaneous oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous oestradiol 0.1 mg/day from day 10 after the LH surge until day 4 of the following cycle
Study: 10325259
Drug: Percutaneous oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous oestradiol 0.1 mg/day
Study: 7758304
Drug: Carbopol gel
Normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol gel with 10% CaNa2-EDTA
Study: 7758304
Drug: Carbopol gel
Normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol gel without CaNa2-EDTA
Study: 7758304
Drug: Nickel alloy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel alloy without barrier gel
Study: 6390659
Drug: Ketotifen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 0.5 mg X 2 daily
Study: 6390659
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg X 2 daily
Study: 6390659
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate 1.34 mg X 2 daily
Study: 29775083
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg IV every 8 h plus enteral nutrition (EN)
Study: 29775083
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg IV every 8 h plus EN
Study: 20220044
Drug: CP‐642,931 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐642,931 (35 mg daily for 7 days)
Study: 7729018
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy in patients with normal LV systolic function
Study: 7729018
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Study: 2372155
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% bupivacaine injected (1 ml every 10 seconds) for spinal anesthesia in group 1 (n = 16)
Study: 2372155
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.5% bupivacaine injected for continuous spinal anesthesia in group 2 (n = 18)
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 15 mg
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) single doses
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) chronic dosing
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 60 mg single dose
Study: 23247938
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg EOW
Study: 9374560
Drug: 1500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/kg of RSVIG (RespiGam, MedImmune Inc, Gaithersburg, MD)
Study: 8193609
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg once daily (increased to 5.0 mg if necessary)
Study: 8193609
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily (increased to 50 mg if necessary)
Study: 8193609
Drug: Cilazapril with
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Study: 8193609
Drug: Captopril with
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Study: 28569519
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus smoking cessation counseling and prolonged exposure therapy (VARCC + PE)
Study: 28147254
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (PE)
Study: 23614971
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% and fentanyl 2 μg/mL
Study: 23614971
Drug: Bupivacaine 0.1%
Normalized name: BUPIVACAINE 0.1%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.1% plus fentanyl 2 μg/mL and epinephrine 2 μg/mL
Study: 16769782
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and 24 hour bed rest
Study: 16769782
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and normal activity
Study: 15229016
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion treatment
Study: 9383230
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months after BMT (early group, n = 23)
Study: 9383230
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) at 18, 20 and 26 months after BMT (late group, n = 22)
Study: 8256243
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (2 mg/day for five months, then 1 mg/day for three months)
Study: 8256243
Drug: Budesonide (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1.6 mg/day for five months, then 0.8 mg/day for three months)
Study: 2863224
Drug: Combined H1-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined H1- and H2-receptor antagonists (clemastine and cimetidine)
Study: 27030325
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone
Study: 2863224
Drug: H1-antagonist clemastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-antagonist clemastine
Study: 26540732
Drug: Intravenous high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high‐dose methylprednisolone treatment
Study: 26540732
Drug: Oral high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high‐dose methylprednisolone treatment
Study: 20624187
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) group
Study: 15718838
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with ALVAC‐HIV (vCP1433) and Lipo‐6T vaccines followed by subcutaneous interleukin‐2 (weeks 16, 24, 32)
Study: 15718838
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy alone (control)
Study: 10695098
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 4 weeks followed by prophylaxis for 24 weeks
Study: 8457027
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to increase reaction to DCP and decrease reaction to DNCB
Study: 8457027
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions to decrease reaction to DCP and increase reaction to DNCB
Study: 3026010
Drug: Sulbactam/ampicillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/ampicillin plus probenecid (1 g probenecid orally and either one vial of sodium sulbactam/ampicillin or two vials intramuscularly; each vial contained 0.5 g of sodium sulbactam and 1 g of sodium ampicillin)
Study: 28629269
Drug: Obstacle aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstacle aquatic therapy
Study: 28629269
Drug: Traditional aquatic
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional aquatic therapy
Study: 23375352
Drug: 1.2 mL
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mL 2% lidocaine infused 3 min prior to IUD insertion
Study: 18521540
Drug: AGI-1067 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGI-1067 (300 mg daily for 12 weeks)
Study: 11237499
Drug: Intra-arterial (i.a.)
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial (i.a.) cisplatinum (CDP) in three-drug regimen
Study: 11237499
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) cisplatinum (CDP) in three-drug regimen
Study: 11237499
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (HDMTX, ADM, IFO) with i.a. CDP
Study: 11237499
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (HDMTX, ADM, IFO) with i.v. CDP
Study: 8292844
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone
Study: 8292844
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone releasing hormone
Study: 22112743
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day)
Study: 18262192
Drug: 2g LUVs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g LUVs infusion
Study: 18262192
Drug: 8g LUVs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8g LUVs infusion
Study: 18262192
Drug: Combined 2g
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 2g and 8g LUVs infusion
Study: 15681956
Drug: Ropivacaine, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine, 0.2% administered at 5 ml/h through the IC catheter for 48 hours
Study: 15681956
Drug: Placebo (NaCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl, 0.9%) administered at 5 ml/h through the IC catheter for 48 hours
Study: 14597107
Drug: Pentamidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine treatment
Study: 10550734
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 120 mg once daily
Study: 10550734
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 180 mg once daily
Study: 10550734
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg once daily (active control)
Study: 8810686
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclosporin (CyA) and methotrexate, mean final dose of 2.97 mg/kg per day CyA
Study: 1921733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 50 mg micronized progesterone
Study: 1921733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 100 mg micronized progesterone
Study: 1921733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + 200 mg micronized progesterone
Study: 1921733
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg micronized 17 beta-oestradiol (E2) + micronized progesterone (various doses)
Study: 7048451
Drug: yohimbine chlorhydrate
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine chlorhydrate (4 mg)
Study: 7048451
Drug: propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (40 mg)
Study: 25892647
Drug: Bicalutamide 150mg
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 150mg once daily
Study: 15823766
Drug: Cefdinir 600
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 600 mg once daily for 10 days
Study: 15823766
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily for 10 days
Study: 2692973
Drug: Flupenthixol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (0.5 mg tablet in the morning, placebo at night)
Study: 2692973
Drug: Sustained-release amitriptyline
Normalized name: amitriptyline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release amitriptyline (25 mg capsule at night, placebo in the morning)
Study: 30782000
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (TH) 40 mg
Study: 30782000
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) 0.9%
Study: 29049653
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 2.5 mg
Study: 29049653
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 5 mg
Study: 29049653
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 10 mg
Study: 29049653
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 20 mg
Study: 29049653
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 40 mg (4-week dose escalation)
Study: 29049653
Drug: Subcutaneous semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous semaglutide 1.0 mg
Study: 18447101
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of bupropion, nicotine patch, and individual counseling for 8 weeks
Study: 16528136
Drug: Ziprasidone (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40-80 mg b.i.d.)
Study: 16528136
Drug: Amisulpride (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50-100 mg b.i.d.)
Study: 11012492
Drug: Peribulbar block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar block with 10 ml of 0.25% bupivacaine
Study: 11012492
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 150 microg.kg‐1
Study: 1329742
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g orally b.i.d.)
Study: 31761958
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin
Study: 19377716
Drug: Oral cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cancer screening by visual inspection (3 rounds between 1996 and 2004)
Study: 19377716
Drug: Oral cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cancer screening by visual inspection
Study: 17576782
Drug: Thrice-daily hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thrice-daily hydrocortisone dosing (mean total daily dose: 8.3 +/- 2.6 mg/m2)
Study: 17576782
Drug: Twice-daily hydrocortisone
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily hydrocortisone dosing (mean total daily dose: 7.6 +/- 2.1 mg/m2)
Study: 17576782
Drug: Morning doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning doses > 4 mg/m2
Study: 17576782
Drug: Evening doses
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening doses > 2.5 mg/m2
Study: 15120772
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied morphine sulfate 10 mg in Intrasite gel
Study: 15120772
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered morphine sulfate 10 mg
Study: 9513329
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and small dose of fentanyl (Group P)
Study: 29800584
Drug: Compound unconditioned
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound unconditioned stimulus (UCS) - electric shock combined with a scream noise
Study: 18246678
Drug: Rehmannia Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehmannia Oral Liquid
Study: 15170087
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (IRT) using rhenium-188-filled balloon system
Study: 11219972
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate followed by i.v. bolus 5-FU
Study: 26374429
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5-FU
Study: 9640152
Drug: remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1